There is an approved dengue vaccine available in various countries around the world.
Dengue is a mosquito-borne viral infection that is common in warm, tropical climates. Infection is caused by any one of four closely related dengue viruses (called serotypes) and these can lead to a wide spectrum of symptoms, including some which are extremely mild to those that may require medical intervention and hospitalization. In Severe Dengue cases, fatalities can occur.
- Dengvaxia (CYD-TDV) is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes.
- TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus, each of which can cause dengue fever or Severe Dengue.
- DV1-DV4 vaccine candidate is now transitioning into the human clinical study. This new vaccine construct, which comprises Nature’s gene-chip peptides bound to a quantum cluster gold nanoparticle delivery system, was shown to have an excellent safety profile in a repeat dose Good Laboratory Practice (GLP) grade toxicology study using a standard industry model.
- TetraVax-DV-TV003 is a live attenuated recombinant tetravalent investigational dengue vaccine. The vaccine was developed by Dr. Stephen Whitehead’s laboratory in NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Dengue vaccine news:
- Please visit Precision Vaccinations for the latest dengue vaccine news.